PPV of depth of gastric wall involvement and BCL10, NF-κB (p65), BAFF, and CD86 molecules for HP dependence of stage IE/IIE1 gastric DLBCL
| Expression of CagA and CagA-signaling molecules in tumor tissue . | No. of gastric DLBCL patients who receive HPE as frontline treatment . | |
|---|---|---|
| HP dependent, n = 35 . | HP independent, n = 28 . | |
| CagA positive | 26 | 7 |
| CagA negative | 9 | 21 |
| PPV for CagA* = 26 of 33 (78.8%) | ||
| Specificity for CagA† = 21 of 27 (75.0%) | ||
| Tumor-infiltrating submucosa or above and CagA (+) (n = 57) | ||
| Yes | 11 | 1 |
| No | 20 | 25 |
| PPV for combined tumor-infiltrating submucosa or above and CagA* = 11 of 12 (91.7%) | ||
| Specificity for combined tumor-infiltrating submucosa or above and CagA† = 25 of 26 (96.2%) | ||
| CagA and CD86 are all positive | ||
| Yes | 22 | 5 |
| No | 13 | 23 |
| PPV for combined CagA and CD86* = 22 of 27 (81.5%) | ||
| Specificity for combined CagA and CD86† = 23 of 28 (82.1%) | ||
| CagA (+) and BCL10 (−) | ||
| Yes | 25 | 1 |
| No | 10 | 27 |
| PPV for combined CagA and BCL10* = 25 of 26 (96.2%) | ||
| Specificity for combined CagA and BCL10† = 27 of 28 (96.4%) | ||
| CagA (+) and NF-κB (p65) (−) | ||
| Yes | 24 | 2 |
| No | 11 | 26 |
| PPV for combined CagA and NF-κB* = 24 of 26 (92.3%) | ||
| Specificity for combined CagA and NF-κB† = 26 of 28 (92.9%) | ||
| CagA (+) and BAFF (−) | ||
| Yes | 23 | 3 |
| No | 12 | 25 |
| PPV for combined CagA and BAFF* = 23 of 26 (88.5%) | ||
| Specificity for combined CagA and BAFF† = 25 of 28 (89.3%) | ||
| Expression of CagA and CagA-signaling molecules in tumor tissue . | No. of gastric DLBCL patients who receive HPE as frontline treatment . | |
|---|---|---|
| HP dependent, n = 35 . | HP independent, n = 28 . | |
| CagA positive | 26 | 7 |
| CagA negative | 9 | 21 |
| PPV for CagA* = 26 of 33 (78.8%) | ||
| Specificity for CagA† = 21 of 27 (75.0%) | ||
| Tumor-infiltrating submucosa or above and CagA (+) (n = 57) | ||
| Yes | 11 | 1 |
| No | 20 | 25 |
| PPV for combined tumor-infiltrating submucosa or above and CagA* = 11 of 12 (91.7%) | ||
| Specificity for combined tumor-infiltrating submucosa or above and CagA† = 25 of 26 (96.2%) | ||
| CagA and CD86 are all positive | ||
| Yes | 22 | 5 |
| No | 13 | 23 |
| PPV for combined CagA and CD86* = 22 of 27 (81.5%) | ||
| Specificity for combined CagA and CD86† = 23 of 28 (82.1%) | ||
| CagA (+) and BCL10 (−) | ||
| Yes | 25 | 1 |
| No | 10 | 27 |
| PPV for combined CagA and BCL10* = 25 of 26 (96.2%) | ||
| Specificity for combined CagA and BCL10† = 27 of 28 (96.4%) | ||
| CagA (+) and NF-κB (p65) (−) | ||
| Yes | 24 | 2 |
| No | 11 | 26 |
| PPV for combined CagA and NF-κB* = 24 of 26 (92.3%) | ||
| Specificity for combined CagA and NF-κB† = 26 of 28 (92.9%) | ||
| CagA (+) and BAFF (−) | ||
| Yes | 23 | 3 |
| No | 12 | 25 |
| PPV for combined CagA and BAFF* = 23 of 26 (88.5%) | ||
| Specificity for combined CagA and BAFF† = 25 of 28 (89.3%) | ||
PPV: Number of HP-dependent cases who had combined CagA expression, and depth of gastric wall involvement or expression of various molecules, such as CD86, BCL10, NF-κB (p65), and BAFF, divided by the number of the total positive cases for respective CagA expression, depth of gastric wall involvement, or expression of various molecules, such as CD86, BCL10, NF-κB (p65), and BAFF.
Specificity: Number of HP-independent cases who had no CagA expression, or who did not simultaneously express CagA, CD86, nuclear expression of BCL10 and NF-κB (p65), or whose tumors were infiltrating muscularis propria/beyond or expressing BAFF/total HP-independent cases.